PSA vs STRO
PSA (PSA) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
PSA (PSA) common stock.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
PSA currently screens at market cap $0. STRO currently screens at market cap $470.8M.
Not investment advice. Open the PSA and STRO stock pages for the full models.
Not investment advice.